This phase II trial is trying to determine the benefit of adding Bevacizumab (an intravenous drug) to chemotherapy treatment with Vinblastine, in children and adolescents with low grade gliomas.
This trial is treating patients with low grade gliomas.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)
Participants in this trial will be randomised into one of two treatment arms. Arm A will include 68 weeks of single agent Vinblastine administered once weekly IV. Arm B will include 68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks.
Recruiting Hospitals Read More